cimzia (certolizumab pegol) recall — Class II (D-0546-2026) · pharmaranks
Class IIOngoing
cimzia (certolizumab pegol) recall
FDA recall D-0546-2026 · initiated May 8, 2026
May cause temporary or medically reversible harm; low probability of serious harm.
Why it was recalled
Lack of Assurance of Sterility
Details
Product
cimzia (certolizumab pegol), 2x200mg/mL PREFILLED SYRINGES (2 single-dose), Rx ONLY, Manufactured by: UCB Inc., Smyrna, GA 30080, a) NDC 50474-710-79, b) Professional sample, NDC 50474-710-80; c) 3 cartons, STARTER KIT, NDC 50474-710-81.
Recalling company
UCB Biosciences Inc.
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
US Nationwide.
Initiated
May 8, 2026
FDA report date
May 27, 2026
This recall is linked to a product we cover: Cimzia →
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.